Recombinant human growth hormone

ApprovedSmall molecule

Changchun GeneScience Pharmaceutical Co., Ltd.

Recombinant human growth hormone is one of 322 small molecule programs targeting Small for gestational age. It is currently in Approved.

Indications

Total Trials

Active Trials

321

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small for Gestational AgeActive, not recruiting

HypochondroplasiaActive, not recruiting

Turner SyndromeActive, not recruiting

LipodystrophyActive, not recruiting

Prader-Willi SyndromeActive, not recruiting

Anorexia NervosaActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Brain InjuryActive, not recruiting

AchondroplasiaActive, not recruiting

Short StatureActive, not recruiting

Small for Gestational AgePhase 3

Active, not recruiting

HypochondroplasiaPhase 2

Active, not recruiting

Turner SyndromePreclinical

Active, not recruiting

LipodystrophyPreclinical

Active, not recruiting

Prader-Willi SyndromePhase 3

Active, not recruiting

Anorexia NervosaPhase 2

Active, not recruiting

Type 2 Diabetes MellitusPhase 3

Active, not recruiting

Brain InjuryPhase 2

Active, not recruiting

AchondroplasiaApproved

Active, not recruiting

Short StaturePreclinical

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Recombinant human growth hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Approved

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Platelet Rich Plasma

ZZagazig University

Preclinical

25 5

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 6

Enbrel

IImmunex

Preclinical

2 7

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 8

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Small for Gestational Age

NCT07309562

Phase 3Recruiting

Short Stature

NCT06927310

Q4 2028

Post-ApprovalNot yet recruiting

Brain Injury

NCT07481656

Phase 1/2Not yet recruiting

Growth Hormone Deficiency

NCT07450001

Phase 1/2Not yet recruiting

Short Stature

NCT07450053

Clinical

Trials by Indication[1]

Growth8 trials

Diet/Growth Factor Mechanisms of Gut Adaptation

Completed·EEmory University·Phase 2·NCT00067860·27 enrolled

Effects of Growth Hormone on Difficult Ventilator Weaning Patients

Completed·NNational Cancer Institute, Egypt·Phase 2·NCT03717168·60 enrolled

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

Completed·SSwathi Sethuram·Phase 2·NCT04003207·6 enrolled

Show 5 more trials

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Recruiting·—·Phase 2·NCT05355272·20 enrolled

Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00287677·33 enrolled

Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS

Completed·—·Phase 1/2·NCT05105685·6 enrolled

Growth Hormone and Glucose Metabolism

Completed·—·Phase 4·NCT00929799·6 enrolled

Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

Completed·MMassachusetts General Hospital·Phase 2·NCT01169103·22 enrolled

Growth Hormone Deficiency5 trials

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

Completed· EMD Serono logo

EMD Serono·Phase 3·NCT00109733·31 enrolled

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

Completed·MMassachusetts General Hospital·N/A·NCT00182091·75 enrolled

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Completed· Teva logo

Teva·Phase 2·NCT01811576·52 enrolled

Show 2 more trials

A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07450001·128 enrolled

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT01187550·214 enrolled

Brain Injury3 trials

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury

Completed·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT00957671·15 enrolled

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Completed·UUniversity of Pennsylvania·Phase 2·NCT00766038·63 enrolled

Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)

Not yet recruiting·—·Phase 4·NCT07481656·160 enrolled

Short stature3 trials

Short Stature and Psychological Well-being

Completed·IIstituto Auxologico Italiano··NCT06295341·80 enrolled

A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)

Not yet recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT07450053·128 enrolled

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Recruiting·XXiamen Amoytop Biotech Co., Ltd.·Phase 3·NCT06927310·300 enrolled

Small for gestational age3 trials

A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA)

Unknown status· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT03245333·120 enrolled

The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age

Recruiting·XXiamen Amoytop Biotech Co., Ltd.·Phase 3·NCT07309562·141 enrolled

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01067352·25 enrolled

14 more indications

Chronic Kidney Disease2 trials

Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease

Terminated·WWeill Medical College of Cornell University·Phase 4·NCT00194961·15 enrolled

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

Unknown status· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT03535415·68 enrolled

Achondroplasia1 trial

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Unknown status· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 4·NCT05353192·38 enrolled

Kidney Failure1 trial

Effect of Cytokines on Growth of Children With Chronic Kidney Failure

Suspended·WWeill Medical College of Cornell University·Phase 4·NCT00194883·50 enrolled

Anorexia Nervosa1 trial

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

Completed·MMassachusetts General Hospital·Phase 2·NCT00283595·21 enrolled

Type 2 Diabetes Mellitus1 trial

Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus

Completed·GGöteborg University·Phase 3·NCT00781547·40 enrolled

Lipodystrophy1 trial

Physiologic Growth Hormone Effects in HIV Lipodystrophy

Completed·MMassachusetts General Hospital·N/A·NCT00100698·56 enrolled

Cardiovascular Risk Factor1 trial

Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Terminated·—·Phase 1/2·NCT00684957·5 enrolled

Turner syndrome1 trial

D3-GHR Polymorphism and Turner Syndrome

Completed·UUniversity Hospital Tuebingen··NCT00443144

Metabolism1 trial

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00183040·108 enrolled

Osteoarthritis1 trial

Human Growth Hormone Injections in the Knee Joint to Treat Osteoarthritis

Suspended·JJohn Sledge·Phase 2·NCT06354023·23 enrolled

Prader-Willi syndrome1 trial

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

Unknown status· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT03554031·30 enrolled

Dialysis Patients1 trial

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

Completed·VVanderbilt University·Phase 2·NCT00244075·46 enrolled

Hypochondroplasia1 trial

Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01111019·19 enrolled

Adult1 trial

A Clinical Study of GenSci134 in Healthy Male Adults

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1·NCT07016802·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Recombinant human growth hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human growth hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human growth hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changchun GeneScience Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Changchun GeneScience Pharmaceutical Co., Ltd.

Recombinant human growth hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Growth8 trials

Growth Hormone Deficiency5 trials

Brain Injury3 trials

Short stature3 trials

Small for gestational age3 trials

Chronic Kidney Disease2 trials

Achondroplasia1 trial

Kidney Failure1 trial

Anorexia Nervosa1 trial

Type 2 Diabetes Mellitus1 trial

Lipodystrophy1 trial

Cardiovascular Risk Factor1 trial

Turner syndrome1 trial

Metabolism1 trial

Osteoarthritis1 trial

Prader-Willi syndrome1 trial

Dialysis Patients1 trial

Hypochondroplasia1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News